1.Savarese G, Becher PM, Lund LH, et al. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res 2023;118:3272–87.
2.McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021;42:3599–726.
3.D’Amario D, Rodolico D, Delvinioti A, et al. Eligibility for the 4 Pharmacological Pillars in Heart Failure With Reduced Ejection Fraction at Discharge. J Am Heart Assoc 2023;12:e029071.
4.Laborante R, Savarese G, Patti G, et al. Safety and efficacy of early initiation of sodium-glucose cotransporter-2 inhibitors after an acute coronary syndrome event: a meta-analysis of randomized controlled trials. Eur Heart J Cardiovasc Pharmacother 2024;10:646–8.
5.Greene SJ, Fonarow GC, Vaduganathan M, et al. The vulnerable phase after hospitalization for heart failure. Nat Rev Cardiol 2015;12:220–9.
6.D’Amario D, Laborante R, Delvinioti A, et al. Generator heart failure DataMart: An integrated framework for heart failure research. Front Cardiovasc Med 2023;10:1104699.
7.Kotecha D, Asselbergs FW, Achenbach S, et al. CODE-EHR best practice framework for the use of structured electronic healthcare records in clinical research. Eur Heart J 2022;43:3578–88.
8.Pierce JB, Vaduganathan M, Fonarow GC, et al. Contemporary Use of Sodium-Glucose Cotransporter-2 Inhibitor Therapy Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction in the US: The Get With The Guidelines-Heart Failure Registry. JAMA Cardiol 2023;8:652–61.
9.Crespo-Leiro MG, Anker SD, Maggioni AP, et al. European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions. Eur J Heart Fail 2016;18:613–25.
10.Chang H-Y, Wang C-C, Wei J, et al. Gap between guidelines and clinical practice in heart failure with reduced ejection fraction: Results from TSOC-HFrEF registry. J Chin Med Assoc 2017;80:750–7.
11.Greene SJ, Ezekowitz JA, Anstrom KJ, et al. Medical Therapy During Hospitalization for Heart Failure With Reduced Ejection Fraction: The Victoria Registry. J Card Fail 2022;28:1063–77.
12.Bozkurt B, Savarese G, Adamsson Eryd S, et al. Mortality, Outcomes, Costs, and Use of Medicines Following a First Heart Failure Hospitalization. JACC: Heart Failure 2023;11:1320–32.
13.Schrage B, Lund LH, Benson L, et al. Association between a hospitalization for heart failure and the initiation/discontinuation of guideline-recommended treatments: An analysis from the Swedish Heart Failure Registry. Eur J Heart Fail 2023;25:1132–44.
14.Savarese G, Bodegard J, Norhammar A, et al. Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study (US, UK and Sweden). Eur J Heart Fail 2021;23:1499–511.
15.Butler J, Yang M, Manzi MA, et al. Clinical Course of Patients With Worsening Heart Failure With Reduced Ejection Fraction. J Am Coll Cardiol 2019;73:935–44.
16.Greene SJ, Ayodele I, Pierce JB, et al. Eligibility and Projected Benefits of Rapid Initiation of Quadruple Therapy for Newly Diagnosed Heart Failure. JACC Heart Fail 2024;12:1365–77.
17.Kane JA, Kim JK, Haidry SA, et al. Discontinuation/Dose Reduction of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers during Acute Decompensated Heart Failure in AfricanAmerican Patients with Reduced Left-Ventricular Ejection Fraction. Cardiology 2017;137:121–5.
18.Gilstrap LG, Fonarow GC, Desai AS, et al. Initiation, Continuation, or Withdrawal of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers and Outcomes in Patients Hospitalized With Heart Failure With Reduced Ejection Fraction. J Am Heart Assoc 2017;6:e004675.
19.Mohanty AF, Levitan EB, King JB, et al. Sacubitril/Valsartan Initiation Among Veterans Who Are Renin-Angiotensin-
Aldosterone System Inhibitor Naïve With Heart Failure and Reduced Ejection Fraction. J Am Heart Assoc 2021;10:e020474.
20.Seferovic JP, Claggett B, Seidelmann SB, et al. Effect of sacubitril/ valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. Lancet Diabetes Endocrinol 2017;5:333–40.
21.Pitt B, Filippatos G, Agarwal R, et al. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med 2021;385:2252–63.
22.Savarese G, Carrero J, Pitt B, et al. Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry. European J of Heart Fail 2018;20:1326–34.
23.Stolfo D, Lund LH, Benson L, et al. Real-world use of sodiumglucose cotransporter 2 inhibitors in patients with heart failure and reduced ejection fraction: Data from the Swedish Heart Failure Registry. Eur J Heart Fail 2023;25:1648–58.
24.Savarese G, Kishi T, Vardeny O, et al. Heart Failure Drug TreatmentInertia, Titration, and Discontinuation: A Multinational Observational Study (EVOLUTION HF). JACC Heart Fail 2023;11:1–14.
25.Stolfo D, Lund LH, Becher PM, et al. Use of evidence-based therapy in heart failure with reduced ejection fraction across age strata. Eur J Heart Fail 2022;24:1047–62.
26.Yi TW, O’Hara DV, Smyth B, et al. Identifying Barriers and Facilitators for Increasing Uptake of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors in British Columbia, Canada, using the Consolidated Framework for Implementation Research. Can J Kidney Health Dis 2024;11:20543581231217857.
27.Wiegley N, So PN. Sodium-Glucose Cotransporter 2 Inhibitors and Urinary Tract Infection: Is There Room for Real Concern? Kidney360 2022;3:1991–3.
28.Kimmoun A, Takagi K, Gall E, et al. Temporal trends in mortality and readmission after acute heart failure: a systematic review and metaregression in the past four decades. Eur J Heart Fail 2021;23:420–31.
29.Taylor CJ, Ordóñez-Mena JM, Roalfe AK, et al. Trends in survival after a diagnosis of heart failure in the United Kingdom 2000-2017: population based cohort study. BMJ 2019;364:l223.
30.Jain V, Minhas AMK, Morris AA, et al. Demographic and Regional Trends of Heart Failure-Related Mortality in Young Adults in the US, 1999-2019. JAMA Cardiol 2022;7:900–4.
31.Desai AS, Claggett BL, Packer M, et al. Influence of Sacubitril/ Valsartan (LCZ696) on 30-Day Readmission After Heart Failure Hospitalization. J Am Coll Cardiol 2016;68:241–8.
32.Vicent L, Cinca J, Vazquez‐García R, et al. Discharge treatment with angiotensin‐converting enzyme inhibitor/angiotensin receptor blocker after a heart failure hospitalisation is associated with a better prognosis irrespective of left ventricular ejection fraction. Intern Med J 2019;49:1505–13.
33.Ter Maaten JM, Martens P, Damman K, et al. Higher doses of loop diuretics limit uptitration of angiotensin-converting enzyme inhibitors in patients with heart failure and reduced ejection fraction. Clin Res Cardiol 2020;109:1048–59.
34.Ezekowitz J, Alemayehu W, Edelmann F, et al. Diuretic use and outcomes in patients with heart failure with reduced ejection fraction: Insights from the VICTORIA trial. Eur J Heart Fail 2024;26:628–37.
35.Kapelios CJ, Laroche C, Crespo-Leiro MG, et al. Association between loop diuretic dose changes and outcomes in chronic heart failure: observations from the ESC-EORP Heart Failure Long-Term Registry. Eur J Heart Fail 2020;22:1424–37.
36.Okabe T, Yakushiji T, Kido T, et al. The association between highdose loop diuretic use at discharge and cardiovascular mortality in patients with heart failure. ESC Heart Fail 2018;5:87–94.
37.Koike T, Suzuki A, Kikuchi N, et al. Prognostic impact of outpatient loop diuretic reduction patterns in patients with chronic heart failure. Int J Cardiol Heart Vasc 2024;55:101517.
38.Hamaguchi S, Kinugawa S, Tsuchihashi-Makaya M, et al. Loop diuretic use at discharge is associated with adverse outcomes in hospitalized patients with heart failure: a report from the Japanese cardiac registry of heart failure in cardiology (JCARE-CARD). Circ J 2012;76:1920–7.
39.Galve E, Mallol A, Catalan R, et al. Clinical and neurohumoral consequences of diuretic withdrawal in patients with chronic, stabilized heart failure and systolic dysfunction. Eur J Heart Fail 2005;7:892–8.
40.Kapelios CJ, Kaldara E, Ntalianis A, et al. Lowering furosemide dose in stable chronic heart failure patients with reduced ejection fraction is not accompanied by decompensation: a randomized study. Int J Cardiol 2014;177:690–2.
41.Felker GM, Ellison DH, Mullens W, et al. Diuretic Therapy for Patients With Heart Failure: JACC State-of-the-Art Review. J Am Coll Cardiol 2020;75:1178–95.